News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News EMA abandons X in favour of rival Bluesky The EMA has abandoned X for Bluesky, saying Elon Musk's social media platform "no longer suits our communication needs."
Sales & Marketing Unpacking EASD 2024: Key themes, topics, and influencers This September, Madrid played host to the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Sales & Marketing Creative review: The Cannes Lions trends that pharma needs t... Pharma creative needs to stand up and be counted.
Digital DIA 2024: Charting new horizons in patient-centered R&D In its 60th year, the Drug Information Association (DIA) global annual meeting
Market Access Deepening perspectives: How social media is driving our unde... On the 31st of May, news broke that the NHS was launching its “world-first” cancer vaccine matchmaking programme.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.